Nomura Securities Maintains a 'Neutral' on DIRECTV (DTV); Review of 2Q Results.
Tweet
Share
E-mailGet Alerts DTV Hot Sheet
Price: $58.01 --0%
Rating Summary:
5 Buy, 22 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 6 | Down: 7 | New: 12
Rating Summary:
5 Buy, 22 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 6 | Down: 7 | New: 12
Join SI Premium – FREE
Nomura Securities maintains a 'Neutral' on DIRECTV (NASDAQ: DTV).
Nomura analyst, Mike McCormack, "There are signs of incremental stress in the US business as US revenue growth at 7% has slowed to the lowest rate since 1Q09 and cash expenses are consistently growing at 8%-9% clip. We believe some degree of caution is warranted. DTVLA exceed expectations and remains the primary investment theme, despite ~75% of consolidated EBITDA and ~85% of FCF being sourced from the US business. We expect the next development in the Latin American business will be adding leverage to the segment. We remain Neutral on the shares. We modestly adjusted our 2011/2012 EPS estimates to $3.38/$3.87 from $3.37/$3.90, respectively."
For more ratings news on DIRECTV click here and for the rating history of DIRECTV click here.
Shares of DIRECTV closed at $45.39 yesterday.
Nomura analyst, Mike McCormack, "There are signs of incremental stress in the US business as US revenue growth at 7% has slowed to the lowest rate since 1Q09 and cash expenses are consistently growing at 8%-9% clip. We believe some degree of caution is warranted. DTVLA exceed expectations and remains the primary investment theme, despite ~75% of consolidated EBITDA and ~85% of FCF being sourced from the US business. We expect the next development in the Latin American business will be adding leverage to the segment. We remain Neutral on the shares. We modestly adjusted our 2011/2012 EPS estimates to $3.38/$3.87 from $3.37/$3.90, respectively."
For more ratings news on DIRECTV click here and for the rating history of DIRECTV click here.
Shares of DIRECTV closed at $45.39 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Wedbush Starts Aktis Oncology (AKTS) at Outperform
- BMO Capital Starts Exelixis (EXEL) at Market Perform
- BMO Capital Starts Ionis Pharmaceuticals (IONS) at Market Perform
Create E-mail Alert Related Categories
Analyst CommentsRelated Entities
NomuraSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
